EZH2 has been found to epigenetically silence the TGF-ß type II receptor (TßRII) and suppress the TGF-ß-Smad-ASCL1 pathway, resulting in elevated ASCL1 expression and promoting SCLC progression [45]. Here, ASCL1 is linked to small cell lung carcinoma.